Cellebrite DI (CLBT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cellebrite DI stock (CLBT) is currently trading at $14.21. Cellebrite DI PE ratio is 46.03. Cellebrite DI PS ratio (Price-to-Sales) is 7.48. Analyst consensus price target for CLBT is $21.67. WallStSmart rates CLBT as Underperform.
- CLBT PE ratio analysis and historical PE chart
- CLBT PS ratio (Price-to-Sales) history and trend
- CLBT intrinsic value — DCF, Graham Number, EPV models
- CLBT stock price prediction 2025 2026 2027 2028 2029 2030
- CLBT fair value vs current price
- CLBT insider transactions and insider buying
- Is CLBT undervalued or overvalued?
- Cellebrite DI financial analysis — revenue, earnings, cash flow
- CLBT Piotroski F-Score and Altman Z-Score
- CLBT analyst price target and Smart Rating
Cellebrite DI
📊 No data available
Try selecting a different time range
CLBT Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Cellebrite DI (CLBT)
CLBT trades 375% above its Graham fair value of $3.00, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Cellebrite DI (CLBT) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in profit margin, institutional own.. Concerns around price/book and eps growth. Mixed signals suggest waiting for clearer direction before acting.
Cellebrite DI (CLBT) Key Strengths (4)
Strong profitability: $17 kept per $100 revenue
53.85% held by institutions, strong professional interest
Mid-cap company balancing growth potential with stability
Solid profitability: $19 profit per $100 equity
Supporting Valuation Data
Cellebrite DI (CLBT) Areas to Watch (5)
Very expensive at 7.3x book value
Earnings barely growing at 1.80%
Premium valuation at 7.5x annual revenue
Decent operational efficiency, solid but not exceptional
Solid revenue growth at 18.10% per year
Supporting Valuation Data
Cellebrite DI (CLBT) Detailed Analysis Report
Overall Assessment
This company scores 48/100 in our Smart Analysis, earning a D+ grade. Out of 9 metrics analyzed, 4 register as strengths (avg 7.5/10) while 5 fall into concern territory (avg 4.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Profit Margin, Institutional Own., Market Cap. Profitability is solid with Return on Equity at 19.10%, Profit Margin at 16.50%.
The Bear Case
The primary concerns are Price/Book, EPS Growth, Price/Sales. Some valuation metrics including Price/Sales (7.48), Price/Book (7.35) suggest expensive pricing. Growth concerns include Revenue Growth at 18.10%, EPS Growth at 1.80%, which may limit upside. Profitability pressure is visible in Operating Margin at 16.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 19.10% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 18.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Price/Book and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CLBT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CLBT's Price-to-Sales ratio of 7.48x sits near its historical average of 8.37x (42th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 55% below its historical high of 16.69x set in Dec 2024, and 92% above its historical low of 3.89x in Sep 2022. Over the past 12 months, the PS ratio has compressed from ~11.9x as trailing revenue scaled faster than the stock price.
Compare CLBT with Competitors
Top SOFTWARE - INFRASTRUCTURE stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Cellebrite DI (CLBT) · TECHNOLOGY › SOFTWARE - INFRASTRUCTURE
The Big Picture
Cellebrite DI is a strong growth company balancing expansion with improving profitability. Revenue reached 476M with 18% growth year-over-year. Profit margins of 16.5% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 1910.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 78M in free cash flow and 82M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Sector dynamics: monitor SOFTWARE - INFRASTRUCTURE industry trends, competitive moves, and regulatory changes that could impact Cellebrite DI.
Bottom Line
Cellebrite DI offers an attractive blend of growth (18% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Cellebrite DI(CLBT)
NASDAQ
TECHNOLOGY
SOFTWARE - INFRASTRUCTURE
USA
Cellebrite DI Ltd. provides digital intelligence solutions for the public and private sectors globally. The company is headquartered in Petah Tikva, Israel.